Blog – The Market Observer

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

LOS ANGELES, CA, Sept. 19, 2024 — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq: IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medical Center, joined ImmixBio subsidiary Nexcella Scientific Advisory Board. Dr. Comenzo is internationally recognized for […]

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

LOS ANGELES, July 08, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy. The […]

The Business Case for Immix Biopharma and CAR T-Cell Therapy for AL Amyloidosis

Harnessing the Power of Your Immune System Chimeric antigen receptor (CAR) T-cell therapy is a groundbreaking approach that utilizes the body’s own immune system to combat certain blood immune disorders. Immix Biopharma has leveraged this technology, amassing data on over 75 patients, and is now focusing its proprietary CAR T system on treating AL Amyloidosis. […]

The Case for CAR-T and AL Amyloidosis

Potential Curative Treatment In the quest for more effective treatments for AL Amyloidosis, CAR-T therapy stands out as a beacon of hope. Immix Biopharma’s pioneering efforts in this field have already shown promising results. Among the 13 patients treated with their innovative NXC-201 therapy, two have demonstrated remarkable outcomes, surviving for nearly two years post-treatment. […]

Dr. Georg Schett: Leading the Charge in CAR-T Therapy

Introduction: At The Market Observer, we’re committed to spotlighting the brightest stars in the universe. Today, we shine our cosmic light on Dr. Georg Schett, a luminary in the field of rheumatology and autoimmune disease therapy. His pioneering work with CAR-T therapy is setting new trajectories in the treatment of severe autoimmune conditions. Recently, Immix […]

The Market Observer Template